

RESEARCH ARTICLE

Open Access

Altered miRNA expression in canine retinas during normal development and in models of retinal degeneration

Sem Genini*, Karina E Guziewicz, William A Beltran and Gustavo D Aguirre*

Abstract

Background: Although more than 246 loci/genes are associated with inherited retinal diseases, the mechanistic events that link genetic mutations to photoreceptor cell death are poorly understood. miRNAs play a relevant role during retinal development and disease. Thus, as a first step in characterizing miRNA involvement during disease expression and progression, we examined miRNAs expression changes in normal retinal development and in four canine models of retinal degenerative disease.

Results: The initial microarray analysis showed that 50 miRNAs were differentially expressed (DE) early (3 vs. 7 wks) in normal retina development, while only 2 were DE between 7 and 16 wks, when the dog retina is fully mature. miRNA expression profiles were similar between dogs affected with *xlpra2*, an early-onset retinal disease caused by a microdeletion in *RPGRORF15*, and normal dogs early in development (3 wks) and at the peak of photoreceptor death (7 wks), when only 2 miRNAs were DE. However, the expression varied much more markedly during the chronic cell death stage at 16 wks (118 up-/55 down-regulated miRNAs). Functional analyses indicated that these DE miRNAs are associated with an increased inflammatory response, as well as cell death/survival. qRT-PCR of selected apoptosis-related miRNAs ("apoptomirs") confirmed the microarray results in *xlpra2*, and extended the analysis to the early-onset retinal diseases *rcd1* (*PDE6B*-mutation) and *erd* (*STK38L*-mutation), as well as the slowly progressing *prcd* (*PRCD*-mutation). The results showed up-regulation of anti-apoptotic (miR-9, -19a, -20, -21, -29b, -146a, -155, -221) and down-regulation of pro-apoptotic (miR-122, -129) apoptomirs in the early-onset diseases and, with few exceptions, also in the *prcd*-mutants.

Conclusions: Our results suggest that apoptomirs might be expressed by diseased retinas in an attempt to counteract the degenerative process. The pattern of expression in diseased retinas mirrored the morphology and cell death kinetics previously described for these diseases. This study suggests that common miRNA regulatory mechanisms may be involved in retinal degeneration processes and provides attractive opportunities for the development of novel miRNA-based therapies to delay the progression of the degenerative process.

Keywords: Apoptomirs, Canine models, *erd*, Inherited retinal disorders, Microarray, miRNA expression profiles, *prcd*, qRT-PCR, *rcd1*, *xlpra2*

Background

The visual process begins in highly specialized photoreceptors (PRs), which are neurons with a complex structure and a unique ability to convert light photons into electrochemical messages. After the initial quantal light absorption by the rhodopsin visual pigments, a signal is

generated in the PR and subsequently transmitted through two different synaptic pathways in the outer and inner plexiform layers. The information is then conveyed to higher visual centers by the ganglion cell axons. To subserve this role, a large number of genes are involved in PR specification, differentiation, and maintenance [1]; and mutations in many of these genes impair PR function and viability. Indeed, of the 246 loci that are associated with retinal degeneration in humans, in 206 the disease-causative genes have been identified [2]. Several genes

* Correspondence: geninis@vet.upenn.edu; gda@vet.upenn.edu
Department of Clinical Studies-Philadelphia, Section of Ophthalmology,
School of Veterinary Medicine, University of Pennsylvania, 3900 Delancey
Street, 19104 Philadelphia, PA, USA

have also been associated with retinal degeneration in animals [3], and at least 24 mutations in 18 genes related to canine retinal degenerations have been identified [4].

Although the number of identified genetic mutations underlying different forms of retinal degeneration is systematically growing, the molecular events and key components that link specific mutations to PR degeneration remain poorly characterized. Multiple pathways, both pro-apoptotic and pro-survival, are associated with PR degeneration [5-9]. Furthermore, epigenetic mechanisms, including miRNA regulation, also play an essential role in the control of the complex visual processes during eye development and disease [10]. miRNAs are small (~20-25 bp), endogenous, non-coding single-stranded regulatory RNA molecules that regulate various cellular functions, including differentiation, proliferation, and cell death/survival (reviewed by [11]). They are expressed in all living organisms in tissue- and developmental stage-specific manner, and are responsible for individual phenotypical variations. miRNAs silence gene expression via cleavage, degradation, and/or translational inhibition of their downstream target mRNAs (reviewed for mammalian miRNAs by [12]). Each miRNA has the potential to regulate multiple different mRNA targets simultaneously, while a given mRNA target might similarly be targeted by multiple miRNAs (reviewed by [13]). The number of known mature miRNAs is currently 30,424 in 193 species and approximately 2,580 have been discovered in humans [14]. Of these, 349 have been linked to 163 different diseases [15].

Recently, the use of miRNA-microarray analysis in several tissues has enabled the identification of altered miRNA transcriptomes during development/aging and disease, including profiles of pathologically altered miRNAs in the eye and retina (reviewed by [16]). Also, it has been shown that miRNA pathways control important steps during the developmental timing of retinogenesis [17], and appear to regulate neuronal differentiation [18]. The use of other technologies (i.e. deep sequencing) has also provided very comprehensive profiles of miRNAs and revealed a complex expression pattern of small RNA in the mouse retina and RPE/choroid [19]. Of particular interest are "apoptomirs" [20], miRNAs that have been shown in many studies to be relevant mediators of cell death signaling [21-23]. Assessment of disease-related miRNAs in human retinal diseases obviously is limited by the availability of appropriately staged tissues from patients having the same disease and causative gene mutation. Notably however, the dog has been widely recognized as an ideal model for a variety of human retinal disease studies, as canine inherited retinopathies result from mutations in disease gene homologues and exhibit comparable phenotypic features, including age

of onset and progression [4]. Some models have the advantage of an early and predictable disease course, making the time window for experimentation very short and easily comparable. As such, they are an ideal system in which to determine if miRNAs are associated with PR death and if their involvement is dependent on the specific mutation driving disease.

To identify potential miRNAs associated with PR degeneration, we used the four following canine models: X-linked progressive retinal atrophy 2 (*xlpra2*), rod cone dysplasia 1 (*rcd1*), early retina degeneration (*erd*), and progressive rod-cone degeneration (*prcd*) that have mutations in *RPGR*, *PDE6B*, *STK38L*, and *PRCD*, respectively. The progression and histopathology in *xlpra2*, *rcd1*, and *erd* are comparable, and characterized by a fast degeneration of the PR cell layer and decreased number of PRs [24-27]. The first two models have mutations in genes that cause human inherited blindness, while no equivalent human disease for *erd* has been reported yet. In contrast, *prcd* is a post-developmental, slowly progressive disease where human patients and animal models show disease variation in the presence of the same mutation [28,29].


For the initial microarray analysis, retinas of dogs affected with *xlpra2* were compared to normal samples. To expand the microarray results, we then undertook a qRT-PCR analysis of the expression of selected apoptomirs in the three additional models, *rcd1*, *erd*, and *prcd*.

Our results show that although different mutations trigger the retinal diseases studied, there are commonalities in the miRNA expression pattern that appear to be associated with the PR cell death kinetics.

Results

miRNA expression profiles of normal and *xlpra2* retinas

We used Affymetrix microarrays to generate comprehensive miRNA expression profiles of retinas from normal and *xlpra2*-mutant dogs. Retinas were examined at 3, 7, and 16 wks of postnatal age, the time points relevant for detection of developmental and degeneration-related miRNAs [24]. In mutant retinas, the 3 wk time point (*induction* phase) is prior to the beginning of apoptosis and retinal structure is normal. The *execution* phase at 7 wks shows a ~10-15% decrease in PR number and is associated with the peak of cell death. Lastly, at the *chronic cell death* phase (16 wks) the mutant retina shows a sustained but reduced cell death rate and a persistent low-grade degeneration with loss of 40% of the PR layer [24]. A heat map illustrating the expression differences of all miRNAs present on the microarray in *xlpra2*-mutants compared to normals (log₂ and FC ratios) at the 3 ages is shown as Figure 1. Only miRNAs showing FC difference > +/-2 and a Benjamini-Hochberg (BH)-adjusted $p < 0.05$ were considered significant, and they are detailed in Additional files 1, 2, and 3. The BH procedure



was applied to control the false discovery rate, which is the proportion of “discoveries” (significant results) that are actually false positives.

Age-dependent miRNA expression changes during development in normal and *xlpra2* retinas-within group comparisons

To properly assess the potential variation in miRNA expression within each experimental group, we first characterized the miRNA expression profile during development of normal retinas by comparing the 3, 7, and 16 wks time points. While the retina is still developing at 3 wks, it reaches structural maturation at 7 wks, and at 16 wks it is

considered fully developed [26]. Results showed that miRNAs in normal retinas were differentially expressed (DE) at 7 vs. 3 wks (27 up-/23 down-regulated) and 16 vs. 3 wks (42 up-/52 down-regulated) (Additional file 1) thus identifying developmentally regulated differences that occur when the retina is developed (7 and 16 wks) or early in differentiation (3 wks). In contrast, there were limited expression differences between the 16 and 7 wk time points (1 up-/1 down-regulated) (Additional file 1). Thus our results suggest that changes in miRNA expression parallel the structural development of the normal dog retina, with major changes occurring between 3 wks and later time points, and minimal differences occurring

between 16 and 7 wks when the retina is fully mature. Although changes in miR-122 expression were not statistically significant due to high variation between biological replicates, it showed the largest FC differences among all miRNAs, being highly down-regulated at 7 compared to 3 wks (FC = -13.2) and 16 wks (FC = -29.6).

In parallel, we examined miRNA expression during development in *xlpra2*-mutant retinas. A total of 37 (21 up-/16 down-regulated) DE miRNAs were identified at 7 vs. 3 wks, 22 (14 up-/8 down-regulated) at 16 vs. 7 wks, and 56 (38 up-/18 down-regulated) at 16 vs. 3 wks (Additional file 2). Interestingly, while the 2 DE miRNAs (miR-363 and -187) in normal retinas between 16 and 7 wks were not DE in *xlpra2* at the same ages, 19 DE miRNAs between 7 and 3 wks (miR-17-5p, -18, -18a, -18b, -29a, -29b-2-star, -29c-star, -34b, -34c, -106a, -106b, -129, -130b, -133a, -133b, -133c, -133d, -211, -363), and 21 between 16 and 3 wks (miR-28, -29a, -29b, -29b-2-star, -29c, -29c-star, -34b, -34c, -34c-3p, -92a-1-star, -130b, -135a-star, -187, -212, -221, -222, -222a, -326, -363, -431, -551a) were DE in both normal and *xlpra2* within group comparisons. The identification of these common DE miRNAs indicates that similar mechanisms occur in normal and *xlpra2* retinas until structural maturation is completed. At later time points, miRNA profiles in mutant retinas are more variable suggesting that miRNA-related mechanisms that may compromise retinal function are activated between these phases of the disease.

miRNA expression changes between normal and *xlpra2*-mutant retinas

To identify miRNAs that are associated with the *xlpra2*-disease process, we directly compared miRNA expression profiles of *xlpra2* and normal retinas at 3 disease phases: *induction*-3 wks, *execution*-7 wks, and *chronic cell death*-16 wks. No differences in miRNA expression were found at 3 wks, and only 2 miRNAs were up-regulated in *xlpra2*-mutants at 7 wks (Additional file 3). Yet at the 16 wk time point, 173 (118 up-/55 down-regulated) miRNAs were DE in *xlpra2* compared to normals (Additional file 3). Of the 2 DE miRNAs identified at 7 wks, only miR-155 was also DE at 16 wks. A graphical illustration of all the DE miRNAs at 16 wks is shown in the heat maps, which illustrate the up- (Figure 2A) and down- (Figure 2B) regulated miRNAs at 16 wks, and their expression patterns at the earlier time points in the disease. Some highly up-regulated miRNAs (e.g. miR-146a, -19a, -21, -101) at 16 wks in *xlpra2* vs. normals also showed high fold change at early ages, although they were not statistically significant (Figure 2A). Of interest was the irregular expression pattern of miR-122 in *xlpra2* compared to normals; although not significant, this miRNA showed the lowest FC


differences at 3 and 16 wks, while it was increased at 7 wks (Figure 2B).

These results demonstrate that whereas miRNA expression differences were minimal during either the *induction* or *execution* phases of the disease, i.e. 3 and 7 wks, a substantial number of altered miRNAs were identified during the *chronic cell death* phase. This suggested that miRNAs would not be the initiators of the PR degeneration process but instead may represent co-effectors and/or arise in response to retinal disease progression.

Functional grouping and target analysis of the DE miRNAs at 16 wks

To further assess the potential functional significance of DE miRNAs during the *chronic cell death* phase of the diseases, we investigated the relationships and common biological functions of the 173 DE miRNAs using the Ingenuity Pathway Analysis (IPA) database. The 7 networks that were significantly associated with the DE miRNAs at 16 wks were: (1) Cancer, Reproductive System Disease, Endocrine System Disorders (23 up- and 3 down-regulated miRNAs, see Additional file 4 for a graphical representation); (2) Connective Tissue Disorders, Inflammatory Disease, Inflammatory Response (11 up- and 10 down-regulated miRNAs); (3) Reproductive System Disease, Connective Tissue Disorders, Inflammatory Disease (13 up- and 5 down-regulated miRNAs); (4) Endocrine System Disorders, Reproductive System Disease, Metabolic Disease (9 up- and 6 down-regulated miRNAs); (5) Reproductive System Disease, Cancer, Respiratory Disease (8 up- and 7 down-regulated miRNAs); (6) Cancer, Gastrointestinal Disease, Hereditary Disorder (14 up-regulated miRNAs); (7) Endocrine System Disorders, Reproductive System Disease, Connective Tissue Disorders (13 up-regulated miRNAs) (Additional file 5). Identified genes and node molecules of particular interest are those with known functional relevance in the retina and/or are related to apoptosis, a hallmark of our disease models. These include *NFkB*, *PARP*, pro-inflammatory cytokines (network 1, Additional file 4), *CREB1* (network 2), *DICER1* (network 3), *PAX6* (network 4), *E2F1*, tretinoin, *VIM* (network 5), *BIRC5*, *SIRT1*, tretinoin (network 6), *IL21*, *Vegf* (network 7).

The 5 IPA biological functions showing the highest association with the misregulated miRNAs were identified and summarized in Additional file 6. Although the DE miRNAs were related to general diseases/disorders including the inflammatory response, of particular interest were DE miRNAs associated with cellular development, cellular growth and proliferation, cell cycle, cell death and survival, and cell-to-cell signaling and interaction. These data suggest involvement of the DE miRNAs in the *chronic cell death* phase and therefore



in the progression of the disease. The results also indicate that the DE miRNAs might be related to the inflammatory response, which has been shown to be relevant during retina degeneration in several diseases [30–32].

Finally, to identify potential target molecules that might be directly affected by over-expression of miRNAs, we determined *in silico* common targets of the highly up-regulated miRNAs at 16 wks (FC > 5, Additional file 3). A total of 35 genes were identified (Table 1), including *CREB1*, one of the genes in IPA network 2 that was already associated with the DE miRNAs (Additional file 5).

qRT-PCR analysis of selected apoptomirs to validate the microarray data and expand the results to additional canine models

Based on the functional analyses and phenotypical evidence of PR cell death, we used qRT-PCR of 11 selected DE apoptomirs to validate the microarray results (Figure 2). The main functions of the selected apoptomirs were anti-apoptotic (miR-9, -19a, -20, -21, -155, -183, -221), pro-apoptotic (-122, -129), or miRNAs with dual anti- and pro-apoptotic properties (-29b, -146a) (for references see Additional file 6). In addition, we characterized changes in apoptomir expression in additional canine models: *rcd1*, *erd*, and *prcd*. Although

Table 1 Common gene targets of all the up-regulated (FC > 5) miRNAs identified at 16 wks

Gene target symbol	Definition	NCBI accession sequences
<i>FBXO28</i>	F-box protein 28	NM_015176; AK303381
<i>BBX</i>	Bobby sox homolog (Drosophila)	NM_020235; NM_001142568
<i>SPRED1</i>	Sprouty-related, EVH1 domain-containing protein 1	NM_152594
<i>MMAA</i>	Methylmalonic aciduria (cobalamin deficiency) type A (mitochondrial)	NM_172250
<i>ST8SIA4</i>	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4	NM_005668
<i>KCNK10</i>	potassium channel, subfamily K, member 10	NM_021161; NM_138317
<i>USP9Y</i>	Ubiquitin specific peptidase 9, Y-linked	NM_004654
<i>ALG11</i>	Asparagine-linked glycosylation 11, alpha-1,2-mannosyltransferase homolog (Yeast)	NM_001004127
<i>DIEXF</i>	Digestive organ expansion factor homolog (Zebrafish)	NM_014388; AK314061
<i>RORA</i>	RAR-related orphan receptor A	NM_002943; NM_134260
<i>PHACTR2</i>	Phosphatase and actin regulator 2	NM_014721; NM_001100164
<i>SNTB2</i>	Syntrophin, beta 2 (dystrophin-associated protein A1, 59 kDa, basic component 2)	NM_006750
<i>BCAT1</i>	Branched chain amino-acid transaminase 1, cytosolic	NM_005504; AK128527
<i>PAG1</i>	Phosphoprotein associated with glycosphingolipid microdomains 1	NM_018440
<i>CREB1</i>	cAMP responsive element binding protein 1	NM_004379; NM_134442
<i>PTAR1</i>	Protein prenyltransferase alpha subunit repeat containing 1	NM_001099666
<i>TFCP2L1</i>	Transcription factor CP2-like 1	NM_014553; AL137740
<i>SLC1A2</i>	Solute carrier family 1 (glial high affinity glutamate transporter), member 2	NM_004171; U01824
<i>ACVR2B</i>	Activin A receptor, type IIB	NM_001106; BC096245
<i>ST8SIA3</i>	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3	NM_015879
<i>UBN2</i>	Ubinuclein 2	NM_173569
<i>ADCY1</i>	Adenylate cyclase 1 (brain)	NM_021116
<i>DNAH14</i>	Dynein, axonemal, heavy chain 14	NM_001373
<i>SSR1</i>	Signal sequence receptor, alpha	NM_003144; CR599599
<i>FUT9</i>	Fucosyltransferase 9 (alpha (1,3) fucosyltransferase)	NM_006581
<i>SCAI</i>	Suppressor of cancer cell invasion	NM_173690; NM_001144877
<i>CDK6</i>	Cyclin-dependent kinase 6	NM_001259; NM_001145306
<i>TNRC6B</i>	Trinucleotide repeat containing 6B	NM_015088; NM_001024843
<i>LOC728264</i>	Homo sapiens cDNA FLJ44517 fis, clone UTERU3002667	AK126481
<i>CBX5</i>	Chromobox homolog 5	NM_012117; NM_001127321
<i>NSL1</i>	Kinetochore-associated protein NSL1 homolog	NM_015471; AK303250
<i>KSR2</i>	Kinase suppressor of ras 2	NM_173598
<i>NEAT1</i>	Nuclear paraspeckle assembly transcript 1	NR_028272
<i>SH3TC2</i>	SH3 domain and tetratricopeptide repeats 2	NM_024577; AB075865
<i>TSIX</i>	X (inactive)-specific transcript, antisense	NR_003255

The complete list of DE miRNAs identified at 16 wks between *xlpra2* and normal retinas is shown in Additional file 3. The 35 common gene targets are reported with their symbols, definitions, and NCBI accession numbers.

there is no observed peak of cell death in the *prcd* disease, PRs begin to degenerate first in the inferior and then in the superior region of the retina after 25 wks, at which time the ERG is altered. This disease is of particular interest for epigenetic control because human and animal patients show phenotypical variations in the presence of the same mutation, both in severity and in affected retinal regions (superior/inferior) [33]. Thus,

the identification of miRNAs as *prcd* modulators that influence the disease phenotypes is relevant to provide insights into this specific disease mechanism.

Expression changes of apoptomirs during development-within group analysis

We initially analyzed the expression of apoptomirs during development in normal retinas. miR-155 was up-regulated

at 3 compared to 7 and 16 wks, while miR-129 and miR-29b showed the opposite trend. miR-122 was highly up-regulated at 16 wks compared to the other two ages, and was down-regulated at 7 vs. 3 wks. Other down-regulated miRNAs included miR-21 at 16 vs. 7, and miR-19a, -20, -221, -146a at 16 vs. 3 wks (Figure 3). In the *xlpra2* mutant retinas, miR-122 was up-regulated at 7 compared to 3 or 16 wks. Expression of additional apoptomirs increased at later ages, e.g. miR-129 and -29b at 7 vs. 3 wks, and miR-21, -221, -29b, -146a at 16 wks compared to early time points (Figure 3).

With few exceptions, the qRT-PCR and the microarray data within groups were in agreement. Although FC differences were similar in both analyses, expression of miR-122 only achieved statistical significance in the qRT-PCR analysis. Also miR-21, -29b at young ages, and miR-146a were found to be DE by qRT-PCR but not microarray analysis. The BH-adjustment of the p-value likely was responsible for these differences, as it was applied in the microarray analysis and not in qRT-PCR.

The qRT-PCR results were different during development in *rcd1*, *erd*, and *prcd* retinas. In *rcd1*, the expression of miR-19a, -155, and -183 did not vary in any of the ages. The remaining miRNAs had a peak of expression at 7 wks; they were all up-regulated vs. 3 wks and miR-9, -20, -21, -155 were also up-regulated vs. 16 wks

(Figure 3). Thus, expression changes in *rcd1* were similar to those in *xlpra2*, although in the latter disease they appeared to be slightly delayed (i.e. between 16–7 wks); these differences reflect the more severe and faster disease course of *rcd1*. In *erd* retinas, apoptomir expression changes were minimal; miR-221 was up-regulated at 11.9-14.1 vs. 6.4 wks, while miR-29b and -146a showed peaks of expression at 8.3-9.9 and 11.9-14.1 wks, respectively (Figure 3). In *prcd* inferior and superior retinas, 3 and 5 miRNAs, respectively, were up-regulated at 24 vs. 10 wks. Two of them (miR-183 and -21) were altered regardless of the retinal location (Figure 3).

The miRNA expression profiles reflect the cell death kinetics and the phenotypical changes observed for the 3 early-onset diseases, which show that *rcd1* is a very aggressive disease with morphological changes occurring early in life, while *xlpra2* and *erd* are more moderate.

Expression changes of apoptomirs between mutant and normal retinas

With the exception of miR-183, all the tested anti-apoptotic apoptomirs were up-regulated in *xlpra2* at 16 wks, and miR-155 also at 7 wks (Figure 4A and B). In contrast, the pro-apoptotic apoptomirs (-122, -129) were down-regulated in *xlpra2* at 16 wks, the time period after the peak of cell death. The expression pattern of miR-122





Figure 3 Expression changes of DE apoptomirs during development. Significant FC differences as measured by qRT-PCR are reported at 7 vs. 3, 16 vs. 7, and 16 vs. 3 wks in normal, *xlpra2*, and *rcd1*; at 8.3/9.9 vs. 6.4, 11.9/14.1 vs. 8.3/9.9, and 11.9/14.1 vs. 6.4 wks in *erd*; and at 24 vs. 10 wks in inferior and superior retinas of *prcd*-mutants. Bars show SD of biological triplicates. Only DE apoptomirs were displayed.



was unique; it was down-regulated at 3 wks and up-regulated at 7 wks in *xlpra2* (Figure 4C). The apoptomirs with dual anti- and pro-apoptotic properties (miR-29b and -146a) were up-regulated in *xlpra2* at 16 wks (Figure 4D). Comparative results between *xlpra2* and normal retinas showed high concordance between the hybridization-based microarrays and the amplification-based technology (qRT-PCR) and comparable FC differences in expression were also observed. The only exception was miR-122, which, as described above, reached statistical significance only in the qRT-PCR analysis. Overall, our results suggest that up-regulation of anti-apoptotic and down-regulation of pro-apoptotic

miRNAs accompany disease progression in the *xlpra2*-mutant retinas.

Similar patterns of apoptomir expression were observed in *rcd1* and *erd* retinas, especially at 16 wks, and the magnitude and time course directly reflected the severity and rate of progression of the diseases (Figure 4). Few apoptomirs were DE at early ages in *rcd1*; i.e. the anti-apoptotic miR-20 and the pro-apoptotic miR-122 were down-regulated at 3 wks, while the anti-apoptotic miR-155 and -221 were up-regulated at 5 wks during the *execution* phase of the disease. At 7 wks, up-regulation was found for miR-155 and -21 in both *rcd1* and *erd*, miR-9, -146a, -221 only in *rcd1*, and miR-19a, -29b only

in erd. In agreement with the results observed in *xlptra2*, notable results for the *rcd1* and *erd* at 16 wks included down-regulation of the pro-apoptotic miR-122 and -129, and up-regulation of almost all anti-apoptotic miRNAs (Figure 4). The only exception was that the expression of miR-221 was not altered in *erd* but was highly up-regulated in the other 2 diseases. These results indicate that the expression of the selected apoptomirs is similar in the 3 early-onset canine models studied and suggest that up-regulation of anti-apoptotic and down-regulation of pro-apoptotic miRNAs may be engaged to counteract the PR degeneration process.

Expression changes of apoptomirs in the slowly progressive *prcd* disease

To determine if the observed changes in apoptomir expression were specific for early-onset diseases, we analyzed their expression in *prcd*, a slowly progressive autosomal recessive retinal disorder. The qRT-PCR results showed that 4 miRNAs (up-regulated: miR-9 and -146a; down-regulated: miR-20 and -21) were DE between 10 wks old *prcd* superior vs. normal retinas and that 4 miRNAs (-19a, -29b, -155, -183) were up-regulated in 10 wks old *prcd* inferior vs. normals (Figure 5A). These findings indicate that DE miRNAs in *prcd* at the early age were region-

specific as none of them was DE in both superior and inferior retinas.

An increased number of DE apoptomirs was found in 24 wks old *prcd* vs. 16 wks normals; eight (up-regulated: miR-9, -20, -21, -29b, -146a, -155, -183; down-regulated: -122) in the inferior and six (up-regulated: miR-9, -20, -21, -29b, -146a; down-regulated: -122) in the superior retina (Figure 5B). In contrast to the 10 wk time point, the data at 24 wks demonstrated a similar pattern of expression in superior and inferior retinas indicating a region-independent involvement of apoptomirs at this later age.

Several similarities in miRNA expression patterns were found between *prcd* and the 3 early-onset diseases. At 10 wks, before PR cell death, DE apoptomirs in the superior *prcd* retina were the same as in *rcd1* at 7 wks and, with the exception of miR-183, the DE apoptomirs in the inferior retina were the same as in *erd* at 8.3-9.9 wks. At 24 wks, when PRs start to die, DE apoptomirs in the superior and inferior retinas were also DE in *xlptra2*, *rcd1*, and *erd* at 16 wks, with the exception of miR-21 that was not DE in *rcd1* (Figure 4). Although *prcd* is slowly progressive and the phenotype is different from the 3 early-onset diseases, the expression profiles of the selected apoptomirs at later ages were similar. Thus, a




Figure 5 Expression changes of apoptomirs in *prcd* vs. normal retinas. Values that significantly differ as measured by qRT-PCR are indicated with an asterisk (*): $p < 0.05$; FC > +/−2). **A)** FC differences between either superior or inferior retinas in 10 wks old *prcd* vs. age and retinal location matched normals. **B)** FC differences between either superior or inferior retinas in 24 wks old *prcd* vs. 16 wks old entire normal retinas.

common reactive response that causes up-regulation of anti-apoptotic and down-regulation of pro-apoptotic apoptomirs appears to be engaged by the PR degeneration process in all 4 models.

Expression changes of apoptomirs in RPE/choroid samples

The RPE cell layer nourishes the adjacent retinal visual cells and, among other functions, serves to transport small molecules to maintain retinal environment (reviewed by [34]). Although the RPE cells do not degenerate in these canine models until many years after the disease onset, we aimed to determine if the observed expression changes in apoptomirs were specific to the retina or also were present in the RPE. To this end, we compared normal, *xlpra2*, *rcd1*, and *erd* RPE/choroid samples at 7 wks. The results revealed that miR-20 and -146a were up-regulated in all 3 diseases, miR-19a in *xlpra2* and *rcd1*, while miR-29b exclusively in *erd* (Figure 6). Of these, only miR-146a in *rcd1* and -29b in *erd* were also DE in retina at the same age (Figure 4). These results indicate specific differences in apoptomir expression at 7 wks in the 2 different cell types, and do not suggest a key role of RPE cells at this age in the transport of apoptomirs to the diseased retinas.

qRT-PCR analysis of genes involved in miRNA biogenesis

To determine if the miRNA expression changes correlated with dysregulation of the entire miRNA machinery, we also examined the age-related expression of *DICER1*, *XPO5*, and *DROSHA*, three genes that are involved in miRNA biogenesis. *DICER1* is also a component of IPA network #3, which was affected by the DE miRNAs at 16 wks (Additional file 3). The qRT-PCR results showed little difference in expression; the miRNA processing

enzyme *DROSHA* was down-regulated in *erd* retinas at 11.9/14.1 wks and at 7 wks in RPE/choroids, while *DICER1* was down-regulated in *erd* RPE/choroids at 7 wks. As no differences were found between normal and *rcd1* or *xlpra2*-mutants at 3, 5, 7, and 16 wks, or normal and *prcd* at 10 and 24 wks, our results support a specific dysregulation of miRNA biogenesis in *erd*-mutants at later ages.

Discussion

miRNA expression profiles in normal and *xlpra2* retinas

The ability to monitor significant changes in a large number of miRNAs simultaneously is a key factor in understanding their function during aging, and in health and disease. This is particularly relevant, as populations of small RNAs have been shown recently to be extremely complex in mouse retina and RPE/choroid cells [19]. We used the microarray technology to expand our knowledge of miRNA-related mechanisms involved in normal PR development and degeneration in *xlpra2* retinas at three key time points previously established for the disease [24].

In normal retina development, miRNA-related changes predominantly occurred between 7–3 wks, with only minimal changes found at later time points when the retina completes development (7 wks) and is structurally and functionally mature (16 wks) [26]. In *xlpra2*, miRNA developmental expression patterns differed, with fewer DE miRNAs between 7–3 wks and an increased number between 16–7 wks, suggesting that the altered expression at later ages is directly related to disease progression.

These results were confirmed by a direct comparison of the expression profiles of *xlpra2* and normal retinas. No DE miRNAs were found at the *induction* phase of




Figure 6 Expression changes of apoptomirs between mutant and normal RPE/choroids. FC differences of apoptomirs as measured by qRT-PCR are shown between *xlpra2*, *rcd1*, and *erd*-mutants compared to normals at 7 wks of age. Bars show SD of biological triplicates and values that significantly differ are indicated with an asterisk (*: $p < 0.05$; $FC > +/-2$).

the disease (3 wks), when the mutant PRs are developing albeit abnormally, only 2 at the *execution* phase (7 wks), and as many as 173 at the *chronic cell death* phase (16 wks). The high number of DE miRNAs identified at this later time point suggests that the observed PR degeneration in our canine model elicits major changes in miRNA expression and that these molecules might play a key role late in disease progression. Similar to studies in mice [35,36], our results also showed unique patterns of miRNA expression changes that were age- and disease stage-dependent. This indicates that DE miRNAs likely have specific functions at different time points in the disease process, and that miRNA-dependent mechanisms triggered during the *chronic cell death* phase of the disease are different from those induced during the *execution* phase.

The observed increase in miR-1 expression was also previously found in the P347S-RHO model [37], rho knockout, D307-rds, and rds null mutants [38] at comparable disease stages. We did not find any changes in expression of either miR-24a, shown to repress apoptosis in the developing *Xenopus* retina [39], or the miRNA-183/96/182 cluster, which is highly expressed in mouse retina and RPE/choroid cells [19] and PR, retinal bipolar, and amacrine cells [35]. This cluster protects the retina from bright light-induced degeneration [40] and syndromic retinal degeneration [41], and is decreased in retinas of transgenic P347S-RHO mice [37]. Although it is difficult to directly compare these results due to differences in experimental conditions, our results indicate that miRNA profiles can be quite similar in different retinal diseases, although model, age, and species specific expression changes also occur.

Target genes of DE miRNAs

Using a bioinformatics approach, we predicted potential common target genes for the up-regulated ($FC > 5$) miRNAs in *xlpra2* at 16 wks. We identified a total of 35 genes, the function of several of which might be related to PR degeneration. *SNTB2* is necessary for eye development in *Drosophila* [42], *SLC1A2* is a glutamate transporter and glutamate reduction was observed in Müller cell in rd1 retina [43], and *CDK6* is involved in retina degeneration in mice [44]. While down-regulation of *CREB1* has been related to PR cell death in mouse models of retinal degeneration [8], an increase in the levels of native *CREB1* has been reported in the *rcd1* dog [45]. In addition, phosphorylation of *CREB1/ATF1* in PRs of human AMD retinas and in those of canine RP models, including *rcd1*, *erd*, and *prcd* during the *chronic phase* of cell death may contribute to a pro-survival response [45]. These target transcript predictions are useful in highlighting the possible miRNA-dependent regulatory mechanisms that underlie retinal degeneration in the *xlpra2*-mutant dogs.

However, additional experimental studies (for a review see [46]) will be required to validate the predicted miRNA target genes and to determine the effect of these miRNAs on the potential targets in retina.

We previously identified 18 down-regulated transcripts in *xlpra2*-mutants at 16 wks of age using custom made retina-specific microarrays [47]. None of these genes were among the common 35 predicted targets found in this study at the same age. This could be due to the particular composition of the microarrays (e.g. limited availability and retina-specificity of the genes analyzed), as well as the low number of DE transcripts found.

Network and functional IPA analyses of DE miRNAs

The IPA software was used to further characterize the changes in miRNA expression at 16 wks. The results indicated an alteration of networks related to the inflammatory response and to cell death and survival. Inflammation accompanies many retina degenerative diseases (reviewed by [32]), including the rd10 mice model of retinitis pigmentosa [31]. In the *xlpra2* model, retinal inflammation occurs early during the disease process, and may consequently influence the expression of correlated miRNAs.

Several pathways have been related to PR cell death and survival [5,9], thus the association of cell death and survival with the observed miRNA signature is particularly provocative. However, since >70% of vertebrate miRNAs are predicted to have at least one target related to cell death/survival, and a single miRNA might regulate a mixture of anti- and pro-apoptotic genes, one must be cautious when categorizing a miRNA by its role in apoptosis (reviewed by [11]).

Apoptomir expression in normal, *xlpra2*, *rcd1*, *erd*, and *prcd*

With this caveat in mind, we selected apoptosis and inflammation related apoptomirs for qRT-PCR to confirm the microarray data and expand the results to 3 additional retinal diseases and cell types (i.e. RPE/choroid). The selected apoptomirs are all expressed in retina and were divided into anti-, pro-, or both properties according to the current literature (Additional file 7). Although this approach does not provide a comprehensive miRNA profiling in the additional diseases, the results gives interesting insights and comparison data to better understand the miRNA-related mechanisms in different canine models.

Apoptomirs regulation during normal canine development was in agreement with studies in other species. We found an increased expression of miR-122 at 16 vs. 3 wks, in agreement with studies in normal adult mice compared to postnatal at day 4 [48]. Our data also showed high expression levels of miR-155 early in development, and low expression of miR-19a and -20 after development is completed. miR-155 was highly expressed at early

developmental stages in *Xenopus* retina [49] and not detected in 3 month old C57BL/6 J mouse retinas [19], while during murine development miR-19a and -20 are highly expressed at early proliferative stages, but barely detectable in adult retina [50]. These results indicate that the selected apoptomirs exert a common role during normal retina development in several species.

The qRT-PCR results also revealed similar patterns of apoptomir expression at 16 wks in the 3 early-onset models and at 24 wks in *prcd*, independent of the retinal region. There is a differential rate of degeneration between superior and inferior quadrants in *prcd*, with the inferior one occurring earlier and being more severe. As the change from disease to degeneration occurs at >25 wks of age [51,52], our results suggest that disease is comparable between superior and inferior quadrants in the 24 wks old retinas analyzed. The similarities in expression with the other diseases are surprising, as *prcd* is a slowly progressive disease and no peak of PR death is observed. Although this might be due to low expression levels in normals, these results provide interesting and unexpected commonalities in the expression of some apoptomirs in the canine models that are independent of the phenotype and kinetics of disease. Further studies with an increased number of miRNAs (e.g. microarrays or quantitative next generation sequencing) will be helpful to confirm these initial observations.

The most relevant qRT-PCR finding showed a specific increase in anti-apoptotic and decrease of pro-apoptotic apoptomir expression in all disease models, suggesting that during the *chronic cell death* phase compensatory mechanisms are activated in the mutant retinas in an attempt to prevent PR cell death. While these mechanisms appear insufficient to stop the degenerative process, they may influence the rate of progression. Expression of additional DE miRNAs identified by microarray analysis reinforced this hypothesis: the anti-apoptotic miR-146b, -148a, and -7 were up-regulated in *xlpra2*, while the pro-apoptotic miR-34b was down-regulated. However, a few exceptions were found; the normally pro-apoptotic let-7 family, miR-15a, and -16 were up-regulated, whereas the anti-apoptotic miR-210 was slightly down-regulated. This might indicate that these miRNAs exert a different function or are involved in the repression of different genes in retina cells. Further analyses are needed to confirm this prediction.

We found up-regulation of miR-29b in old compared to young normal retinas and in mutants vs. normals during the *chronic cell death* phase. This was in agreement with expression pattern in normal mouse retina and in *Nrl^{-/-}* retinas compared to wild type [53]. We also found an increased expression of miR-146a, -155, -9, -21 in mutants. Up-regulation of miR-146a, -155, and -9 was found in age-related macular degeneration [54], while miR-146a,

-155, and -21 were up-regulated in P347S-RHO mutants [37]. Yet, the expression pattern of miR-29b and -146a, the apoptomirs with known dual anti- and pro-apoptotic properties, was similar to that of anti-apoptotic miRNAs suggesting that in retinal diseases these two miRNAs might be involved in apoptosis repression.

Expression of genes involved in miRNA biogenesis

Our results indicate that retinas and RPE/choroids of *xlpra2*, *rcd1*, and *prcd*-mutants have normal expression patterns of effectors required for miRNA biogenesis, suggesting that the miRNA production machinery is not directly responsible for the alteration of the miRNA profiles. In contrast, *DROSHA* was down-regulated in both the retina and RPE/choroids and *DICER1* in RPE/choroids of *erd* mutants, indicating a dysfunctional miRNA metabolism. Notably, conditional DICER deletion studies in the mouse visual system lead to multiple retinal phenotypes, including increased apoptosis and impaired retinal development, differentiation, and maintenance (reviewed by [16]). The relevance of these observations to the *erd* model, which showed particular disease-specific features such as concomitant PR cell death and proliferation with formation of hybrid rod/S-cones [27], needs further examination.

Conclusions

In the current study we found a number of DE miRNAs at the late stage of the *xlpra2* disease. We then confirmed differential expression of selected apoptosis-related miRNAs by qRT-PCR and found a similar pattern of expression in *rcd1* and to a lesser extent in *erd* and *prcd*. These results showed a general up-regulation of anti-apoptotic and down-regulation of pro-apoptotic miRNAs, suggesting that these miRNAs might be engaged to counteract the degenerative processes. Although different mutations trigger the retinal diseases studied, we observed commonalities in the miRNA expression pattern that appear to be associated with the PR cell death kinetics. These findings are highly significant as they suggest that the use of miRNAs as targets for future therapeutic design might be effective in treating the chronic slow cell death phase of retinal degenerative diseases regardless of the initiating mutation.

Methods

Tissue samples

Retinal tissues were collected from age-matched normal and mutant dogs under deep pentobarbital anesthesia, and the dogs were then euthanatized. The dogs are maintained at the Retinal Disease Studies Facility in Kennett Square, Pennsylvania, and have a common genetic background but differ primarily at the investigated retinal disease locus [4]. To avoid fluctuations in gene expression with time of the day [55], eyes were collected at a single

time period (noon) as previously reported [47]. The research was conducted in full compliance and strict accordance with the Association for Research in Vision and Ophthalmology (ARVO) Resolution on the Use of Animals in Ophthalmic and Vision Research, and all protocols were approved by the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC). All efforts were made to minimize suffering.

Retinal diseases

Four different canine models were studied: **a)** X-linked progressive retinal atrophy 2 (*xlpra2*) is the dog homolog of X-linked retinitis pigmentosa (XLRP). The disease is early-onset, affects rods and cones, and is caused by a 2-bp microdeletion in *RPGR* exon ORF15 that creates a frameshift and premature stop in the translated protein [56]. Although the function of *RPGR* is not yet entirely understood, it has been shown that the protein localizes to the connecting cilium and participates in intraflagellar protein transport, being essential for PR viability and ciliogenesis (reviewed by [57]; **b)** rod cone dysplasia 1 (*rcdl*) is an early-onset, autosomal recessive rod disease caused by a nonsense mutation in the rod cyclic GMP phosphodiesterase 6 β subunit (*PDE6B*) that results in a stop codon and truncation of the protein by 49 aa [58,59]. Cone PRs are not affected by the mutation, but also degenerate secondarily; **c)** early retinal degeneration (*erd*) results from a mutation in *STK38L* that appears to play a role in early PR development [27,60]. Abnormal development and degeneration of rods and cones characterize the disease and, as a unique feature, concurrent PR apoptosis or mitosis, and formation of hybrid rod/S-cone cells occur [27]. *STK38L* function in PRs is currently unknown, but recent *in vitro* studies indicate that *STK38L*-mediated Rabin8 phosphorylation is crucial for ciliogenesis [61]; **d)** *prcd* is a post-developmental, slowly progressive autosomal recessive disorder [29]. The function of the mutant gene *PRCD* is still unknown. Unlike the other three diseases, *prcd* is characterized by a topographically distinct pattern of disease distribution. Early and mild PR outer segment disease is present uniformly across the retina at 10 wks of age, but degeneration begins in the inferior retina after 25 wks of age and progresses more rapidly [51,52]. To address these topographic differences, the globes from *prcd*-affected dogs were hemisected in the horizontal plane and the superior and inferior retina was isolated and analyzed separately.

RNA extraction

Total RNA from neuroretina and retinal pigment epithelium (RPE)/choroid was extracted following standard TRIzol procedures (Invitrogen-Life Technologies, Carlsbad, CA). RNA concentration was assessed with a ND-1000 Spectrophotometer[®] (NanoDrop Technologies, Thermo

Fisher Scientific, Wilmington, DE), and RNA quality verified by microcapillary electrophoresis on an Agilent 2100 Bioanalyzer with RNA 6000 Nanochips (Agilent Technologies, Santa Clara, CA). Only high quality RNA with RIN >7 and A260/280 ratio >1.9 was used in both microarray and qRT-PCR analyses.

Experimental time points and microarray analyses

We initially compared the miRNA expression profiles of normal and *xlpra2* dog retinas at 3, 7, and 16 wks, which are crucial ages in the progression of this disease [24]. A minimum of 3 biological replicates/age/group were analyzed [except for normals (3 and 16 wks) and mutant (7 wks) where 4 biological samples/age were used] with miRNA-specific Affymetrix microarrays (GeneChip miRNA Array) containing a total of 46,228 probes, 7,815 probe sets among which 177 are canine specific miRNAs.

Microarray target preparation and hybridization

Microarray services were provided by the Penn Microarray Facility. All protocols were conducted as described in the standard Affymetrix Expression Analysis Technical Manual (Affymetrix Inc., Santa Clara, CA). Briefly, biotinylated cRNA was prepared from 100 ng total RNA; following fragmentation, cRNA was hybridized for 16 h at 45°C on the Affymetrix miRNA-specific arrays. Microarrays were then washed at low (6X SSPE) and high (100 mM MES, 0.1 M NaCl) stringency and stained with streptavidin-phycoerythrin in an Affymetrix Fluidics Station 400. Fluorescence was amplified by adding biotinylated anti-streptavidin and an additional aliquot of streptavidin-phycoerythrin stain. A confocal scanner (Hewlett-Packard Gene Array Scanner G2500A) was used to collect fluorescence signal after excitation at 570 nm.

Bioinformatic analyses

Affymetrix command console and expression console were used to quantitate expression levels for targeted miRNAs; default values provided by Affymetrix were applied to all analysis parameters. Border pixels were removed, and the average intensity of pixels within the 75th percentile was computed for each probe. The average of the lowest 2% of probe intensities occurring in each of 16 microarray sectors was set as background and subtracted from all features in that sector. Probe sets for positive and negative controls were examined in expression console, and facility quality control parameters were confirmed to fall within normal ranges. Probes for each targeted miRNA were averaged, log transformed, and inter-array normalization performed using the Robust Multichip Analysis (RMA) algorithm. Unsupervised hierarchical clustering by sample was performed to confirm that replicates within each condition grouped with most similarity, and to identify any outlier samples. A two-way

ANOVA with Benjamini-Hochberg (BH)-adjusted $p < 0.05$ and fold change (FC) $> +/-2$ was applied to generate lists of statistically significant DE miRNAs in pairwise comparisons of replicate averages between conditions. On the Affymetrix microarrays there are several probes for the same miRNA that have the same exact sequence, yet a different nomenclature (different species name) (e.g. cfa-miR-155, hsa-miR-155, bta-miR-155, mml-miR-155, ...). Thus, when a miRNA (e.g. -155) represented by several identical probes was DE, we report in the Results section by order of priority the canine (cfa) probe, then the human (hsa). If none of these were represented, we list the one with the species name that has the highest FC difference.

The Ingenuity Pathways Analysis (IPA) database and web-based analysis software (Ingenuity Systems, Inc., Redwood City, CA) [62] was used to identify networks, biological functions, and functional processes that were most significantly associated with the set of DE miRNAs at 16 wks of age.

Furthermore, a target prediction software available online [63] was utilized to predict possible common targets of the up-regulated (FC > 5) miRNAs at 16 wks that had homologues in humans. This comprehensive resource of miRNA target predictions is a development of the miRanda algorithm and uses a compendium of mammalian miRNAs and the mirSVR regression method for predicting likelihood of target mRNAs [64].

Quantitative real-time PCR (qRT-PCR)

qRT-PCR was used to validate the microarray results of 9 DE apoptomirs, as well as miR-122 and -183, in *xlpra2* and normal retinas at 3, 7, and 16 wks. These analyses also included the 5 wk time period in both groups (3 dogs/age/group). The studies were extended to three additional diseases: **a)** *rcd1* at the same 4 time points; **b)** *erd*-mutants at 6.4 wks ($n = 2$) and 8.3-9.9 wks ($n = 3$) compared to the 7 wks normal and 11.9-14.1 wks ($n = 2$) compared to the 16 wk old normal; **c)** *prcd*-mutant inferior and superior retinas at 10 wks compared to inferior and superior retinas of normal dogs at the same age, and, as only minor miRNA expression changes were observed at 24 wks, both 24 wks old inferior and superior *prcd* retinas were also compared to 16 wks old normal entire retinas (3 dogs/age/group).

Lastly, RPE/choroids of normal, *xlpra2*, *rcd1*, and *erd* dogs at 7 wks were also analyzed to determine if the observed changes were retina-specific or if they also occurred in neighboring cells.

Eleven miRNAs (Additional file 7) were tested by qRT-PCR with either human or mouse TaqMan assays to amplify canine sequences (Applied Biosystems, Foster City, CA). U43 was used as housekeeping miRNA because its expression was uniform in all tested dogs in the microarray

and qRT-PCR analyses. To analyze the expression of 4 genes involved in miRNA biogenesis (Additional file 7), RNA samples were treated with RNase-free DNase (Ambion, Austin, TX), and reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The real-time reactions included 30 ng of cDNA and canine specific TaqMan probes. Glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) was used as housekeeping control because in the tested diseases it performed most accurately, and with the least variation between samples [27,47].

All the qRT-PCR reactions were performed in 96 well plates using an ABI 7500 real-time PCR machine with the 7500 detection software (v2.0.1, Applied Biosystems). Comparisons were performed with the $\Delta\Delta CT$ method [65] and statistical significance was verified with an unpaired t-test ($p < 0.05$) and FC $> +/-2$.

Availability of supporting data

The complete microarray data set supporting the results of this article were deposited in NCBI's Gene Expression Omnibus [66] following the guidelines of the rationale of minimum information about a microarray experiment (MIAME), and are accessible through GEO Series accession number GSE35205.

Additional files

Additional file 1: DE miRNAs in normal retinas at different ages. DE miRNAs (BH-adjusted $p < 0.05$ and FC $> +/-2$) identified by microarray analysis in normal retinas at 7 vs. 3, 16 vs. 7, and 16 vs. 3 wks of age. miRNAs are listed from the highest to the lowest fold change difference. In green, apoptomirs tested by qRT-PCR with the corresponding p-value and FC difference.

Additional file 2: DE miRNAs in *xlpra2*-mutant retinas at different ages. DE miRNAs (BH-adjusted $p < 0.05$ and FC $> +/-2$) identified by microarray analysis in *xlpra2*-mutant retinas at 7 vs. 3, 16 vs. 7, and 16 vs. 3 wks of age. miRNAs are listed from the highest to the lowest fold change difference. In green, apoptomirs tested by qRT-PCR with the corresponding p-value and FC difference.

Additional file 3: DE miRNAs between *xlpra2* and normal retinas. DE miRNAs (BH-adjusted $p < 0.05$ and FC $> +/-2$) identified by microarray analysis at 7 and 16 wks of age in *xlpra2*-mutants compared to normals. miRNAs are listed from the highest to the lowest fold change difference. In green, apoptomirs tested by qRT-PCR with the corresponding p-value and FC difference. No expression differences were found at 3 wks.

Additional file 4: IPA network "Cancer, Reproductive System Disease, Endocrine System Disorders" significantly affected by DE miRNAs. Most significantly affected IPA network "Cancer, Reproductive System Disease, Endocrine System Disorders" identified with 23 up-regulated (marked in red) and 3 down-regulated (marked in green) miRNAs that were DE by microarray analysis at 16 wks between *xlpra2* and normal retinas. The complete list of miRNAs and genes belonging to this network and the additional 6 significantly affected networks are detailed in Additional file 5. The figure was adapted from Ingenuity Systems [62].

Additional file 5: IPA networks associated with the DE miRNAs at 16 wks. The 7 IPA affected networks that were associated with the DE miRNAs identified at 16 wks between *xlpra2* and normal retinas are listed with the number (in bold in red up- and green down-regulated), all node

molecules that belong to the network, and the corresponding main functions. A graphical representation of network 1 is shown in Additional file 4.

Additional file 6: IPA biological functions associated with the DE miRNAs at 16 wks. The IPA five most affected biological functions ($p < 0.05$) that belong to the categories "Diseases and Disorders" and "Molecular and Cellular Functions" are reported. The biological functions are shown with the affected sub-groups (from the lowest to the highest p -values), p -values, and the corresponding DE miRNAs.

Additional file 7: qRT-PCR assays used to examine the expression of miRNAs or genes involved in miRNA biogenesis. The miRNA and gene specific TaqMan expression assays (Applied Biosystems catalog #) used for qRT-PCR are reported with the currently known apoptosis-related function and selected references [11,16,40,67-87].

Abbreviations

AMD: Age-related macular degeneration; Apoptomirs: Apoptosis-related miRNAs; ARVO: Association for Research in Vision and Ophthalmology; ATF1: Activating transcription factor 1; BH: Benjamini Hochberg; BIRCS: Baculoviral IAP repeat containing 5; CDK6: Cyclin-dependent kinase 6; CREB1: cAMP responsive element binding protein 1; DE: Differentially expressed; erd: Early retina degeneration; DNAH14: Dynein, axonemal, heavy chain 14; ERG: Electroretinography; E2F1: E2F transcription factor 1; FC: Fold change; *GAPDH*: Glyceraldehyde 3-phosphate dehydrogenase; IACUC: Institutional Animal Care and Use Committee; IL21: Interleukin 21; IPA: Ingenuity Pathway Analysis; KSR2: Kinase suppressor of ras 2; MIAME: Minimum information about a microarray experiment; miRNA and miR: microRNA; NFKB: Nuclear factor of kappa light polypeptide gene enhancer in B-cells; PAG1: Phosphoprotein associated with glycosphingolipid microdomains 1; PARP: Poly (ADP-ribose) polymerase family; PAX6: Paired box 6; PDE6B: Rod cyclic GMP phosphodiesterase 6 β subunit; PR: Photoreceptor; prcd: Progressive rod-cone degeneration; qRT-PCR: Quantitative real-time PCR; rcd1: Rod cone dysplasia 1; RIN: RNA integrity number; RMA: Robust Multichip Analysis; RPE: Retinal pigment epithelium; RPGR: Retinitis pigmentosa GTPase regulator; SCA1: Suppressor of cancer cell invasion; SD: Standard deviation; SIRT1: Sirtuin 1; SLC1A2: Solute carrier family 1 (glial high affinity glutamate transporter) member 2; SNTB2: Syntrophin beta 2; STK38L: Serine/threonine kinase 38 like; Vegf: Vascular endothelial growth factor; VIM: Vimentin; wks: Weeks; xlpra2: X-linked progressive retinal atrophy 2; XLRP: X-linked retinitis pigmentosa; XPO5: Exportin 5.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SG, KEG, WAB, GDA conceived and designed the experiments, analyzed the data, and wrote the paper. All authors read and approved the final manuscript.

Acknowledgements

This study was supported by the Foundation Fighting Blindness (FFB), NIH Grants EY06855, EY017549, R24EY022012, and P30-EY001583, the Van Sloun Fund for Canine Genetic Research, Hope for Vision, and Macula Vision Research Foundation. The authors are grateful to Dr. G. Pertica, E. Santana, J. Slavik, and S. Savina for excellent technical assistance, Dr. D. Baldwin from the UPenn Microarray Facility for the microarray analyses, Dr. J. Tobias from the UPenn Bioinformatics Core for statistical analyses of the microarray data, K. Carlisle and the staff of the Retinal Disease Studies Facility for animal care, M. Leonard for illustrations and figures, and Dr. L. King for critical review of the manuscript and helpful comments.

Received: 7 December 2013 Accepted: 17 February 2014

Published: 1 March 2014

References

1. Swaroop A, Kim D, Forrest D: **Transcriptional regulation of photoreceptor development and homeostasis in the mammalian retina.** *Nat Rev Neurosci* 2010, **11**(8):563-576.
2. **Retinal Information Network (RetNet).** [http://www.sph.uth.tmc.edu/RetNet/]

3. Baehr W, Frederick JM: **Naturally occurring animal models with outer retina phenotypes.** *Vision Res* 2009, **49**(22):2636-2652.
4. Miyadera K, Acland GM, Aguirre GD: **Genetic and phenotypic variations of inherited retinal diseases in dogs: the power of within- and across-breed studies.** *Mamm Genome* 2012, **23**(1-2):40-61.
5. Wright AF, Chakarova CF, Abd El-Aziz MM, Bhattacharya SS: **Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait.** *Nat Rev Genet* 2010, **11**(4):273-284.
6. Wenzel A, Grimm C, Samardzija M, Reme CE: **Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration.** *Prog Retin Eye Res* 2005, **24**(2):275-306.
7. Lohr HR, Kuntchithapatham K, Sharma AK, Rohrer B: **Multiple, parallel cellular suicide mechanisms participate in photoreceptor cell death.** *Exp Eye Res* 2006, **83**(2):380-389.
8. Sancho-Pelluz J, Arango-Gonzalez B, Kustermann S, Romero FJ, van Veen T, Zrenner E, Ekstrom P, Paquet-Durand F: **Photoreceptor cell death mechanisms in inherited retinal degeneration.** *Mol Neurobiol* 2008, **38**(3):253-269.
9. Cottet S, Schorderet DF: **Mechanisms of apoptosis in retinitis pigmentosa.** *Curr Mol Med* 2009, **9**(3):375-383.
10. Cvekl A, Mitton KP: **Epigenetic regulatory mechanisms in vertebrate eye development and disease.** *Heredity (Edinb)* 2010, **105**(1):135-151.
11. Wang Z: **MicroRNA: a matter of life or death.** *World J Biol Chem* 2010, **1**(4):41-54.
12. Grimson A, Farh KK, Johnston WK, Garrett-Engle P, Lim LP, Bartel DP: **MicroRNA targeting specificity in mammals: determinants beyond seed pairing.** *Mol Cell* 2007, **27**(1):91-105.
13. Thomson DW, Bracken CP, Goodall GJ: **Experimental strategies for microRNA target identification.** *Nucleic Acids Res* 2011, **39**(16):6845-6853.
14. **miRBase 20: the microRNA database.** [http://www.mirbase.org]
15. **miR2Disease database.** http://www.mir2disease.org.
16. Maiorano NA, Hindges R: **Non-coding RNAs in retinal development.** *Int J Mol Sci* 2012, **13**(1):558-578.
17. La Torre A, Georgi S, Reh TA: **Conserved microRNA pathway regulates developmental timing of retinal neurogenesis.** *Proc Natl Acad Sci U S A* 2013, **110**(26):E2362-70.
18. Cremiti F: **MicroRNAs and cell fate in cortical and retinal development.** *Front Cell Neurosci* 2013, **7**:141.
19. Soundara Pandi SP, Chen M, Guduric-Fuchs J, Xu H, Simpson DA: **Extremely complex populations of small RNAs in the mouse retina and RPE/choroid.** *Invest Ophthalmol Vis Sci* 2013, **54**(13):8140-8151.
20. Vecchione A, Croce CM: **Apoptomirs: small molecules have gained the license to kill.** *Endocr Relat Cancer* 2010, **17**(1):F37-50.
21. Aranha MM, Santos DM, Xavier JM, Low WC, Steer CJ, Sola S, Rodrigues CM: **Apoptosis-associated microRNAs are modulated in mouse, rat and human neural differentiation.** *BMC Genomics* 2010, **11**:514.
22. Garofalo M, Condorelli GL, Croce CM, Condorelli G: **MicroRNAs as regulators of death receptors signaling.** *Cell Death Differ* 2010, **17**(2):200-208.
23. Wang Y, Lee CG: **MicroRNA and cancer-focus on apoptosis.** *J Cell Mol Med* 2009, **13**(1):12-23.
24. Beltran WA, Hammond P, Acland GM, Aguirre GD: **A frameshift mutation in RPGR exon ORF15 causes photoreceptor degeneration and inner retina remodeling in a model of X-linked retinitis pigmentosa.** *Invest Ophthalmol Vis Sci* 2006, **47**(4):1669-1681.
25. Farber DB, Danciger JS, Aguirre G: **The beta subunit of cyclic GMP phosphodiesterase mRNA is deficient in canine rod-cone dysplasia 1.** *Neuron* 1992, **9**(2):349-356.
26. Acland GM, Aguirre GD: **Retinal degenerations in the dog: IV. Early retinal degeneration (erd) in Norwegian elkhounds.** *Exp Eye Res* 1987, **44**(4):491-521.
27. Berta AI, Boesze-Battaglia K, Genini S, Goldstein O, O'Brien PJ, Szel A, Acland GM, Beltran WA, Aguirre GD: **Photoreceptor cell death, proliferation and formation of hybrid Rod/S-cone photoreceptors in the degenerating STK38L mutant retina.** *PLoS One* 2011, **6**(9):e24074.
28. Pach J, Kohl S, Gekeler F, Zobor D: **Identification of a novel mutation in the PRCD gene causing autosomal recessive retinitis pigmentosa in a Turkish family.** *Mol Vis* 2013, **19**:1350-1355.
29. Zangerl B, Goldstein O, Philp AR, Lindauer SJ, Pearce-Kelling SE, Mullins RF, Graphodatsky AS, Ripoll D, Felix JS, Stone EM, Acland GM, Aguirre GD: **Identical mutation in a novel retinal gene causes progressive rod-cone degeneration in dogs and retinitis pigmentosa in humans.** *Genomics* 2006, **88**(5):551-563.

30. Forrester JV: **Bowman lecture on the role of inflammation in degenerative disease of the eye.** *Eye (Lond)* 2013, **27**(3):340–352.
31. Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Enaida H, Ishibashi T: **Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa.** *Ophthalmology* 2013, **120**(1):e5–e12.
32. Viringipurampeer IA, Bashar AE, Gregory-Evans CY, Moritz OL, Gregory-Evans K: **Targeting inflammation in emerging therapies for genetic retinal disease.** *Int J Inflamm* 2013, **2013**:581751.
33. Aguirre GD, Acland GM: **Variation in retinal degeneration phenotype inherited at the *prcd* locus.** *Exp Eye Res* 1988, **46**(5):663–687.
34. Strauss O: **The retinal pigment epithelium in visual function.** *Physiol Rev* 2005, **85**(3):845–881.
35. Xu S, Witmer PD, Lumayag S, Kovacs B, Valle D: **MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster.** *J Biol Chem* 2007, **282**(34):25053–25066.
36. Xu S: **microRNA expression in the eyes and their significance in relation to functions.** *Prog Retin Eye Res* 2009, **28**(2):87–116.
37. Loscher CJ, Hokamp K, Kenna PF, Ivens AC, Humphries P, Palfi A, Farrar GJ: **Altered retinal microRNA expression profile in a mouse model of retinitis pigmentosa.** *Genome Biol* 2007, **8**(11):R248.
38. Loscher CJ, Hokamp K, Wilson JH, Li T, Humphries P, Farrar GJ, Palfi A: **A common microRNA signature in mouse models of retinal degeneration.** *Exp Eye Res* 2008, **87**(6):529–534.
39. Walker JC, Harland RM: **microRNA-24a is required to repress apoptosis in the developing neural retina.** *Genes Dev* 2009, **23**(9):1046–1051.
40. Zhu Q, Sun W, Okano K, Chen Y, Zhang N, Maeda T, Palczewski K: **Sponge transgenic mouse model reveals important roles for the MicroRNA-183 (miR-183)/96/182 cluster in postmitotic photoreceptors of the retina.** *J Biol Chem* 2011, **286**(36):31749–31760.
41. Lumayag S, Haldin CE, Corbett NJ, Wahlin KJ, Cowan C, Turturro S, Larsen PE, Kovacs B, Witmer PD, Valle D, Zack DJ, Nicholson DA, Xu S: **Inactivation of the microRNA-183/96/182 cluster results in syndromic retinal degeneration.** *Proc Natl Acad Sci U S A* 2013, **110**(6):E507–16.
42. Nagai R, Hashimoto R, Tanaka Y, Taguchi O, Sato M, Matsukage A, Yamaguchi M: **Syntrophin-2 is required for eye development in *Drosophila*.** *Exp Cell Res* 2010, **316**(2):272–285.
43. Gibson R, Fletcher EL, Vingrys AJ, Zhu Y, Vessey KA, Kalloniatis M: **Functional and neurochemical development in the normal and degenerating mouse retina.** *J Comp Neurol* 2013, **521**(6):1251–1267.
44. Zencak D, Schouwey K, Chen D, Ekstrom P, Tanger E, Bremner R, van Lohuizen M, Arsenijevic Y: **Retinal degeneration depends on Bmi1 function and reactivation of cell cycle proteins.** *Proc Natl Acad Sci U S A* 2013, **110**(7):E593–601.
45. Beltran WA, Allore HG, Johnson E, Towle V, Tao W, Acland GM, Aguirre GD, Zeiss CJ: **CREB1/ATF1 activation in photoreceptor degeneration and protection.** *Invest Ophthalmol Vis Sci* 2009, **50**(11):5355–5363.
46. Ritchie W, Rasko JE, Flamant S: **MicroRNA target prediction and validation.** *Adv Exp Med Biol* 2013, **774**:39–53.
47. Genini S, Zangerl B, Slavik J, Acland G, Beltran WA, Aguirre GD: **Transcriptional profile analysis of RPRORF15 frameshift mutation identifies novel genes associated with retinal degeneration.** *Invest Ophthalmol Vis Sci* 2010, **51**(11):6038–6050.
48. Arora A, Guduric-Fuchs J, Harwood L, Dellett M, Cogliati T, Simpson DA: **Prediction of microRNAs affecting mRNA expression during retinal development.** *BMC Dev Biol* 2010, **10**:1.
49. Decembrini S, Bressan D, Vignali R, Pitto L, Mariotti S, Rainaldi G, Wang X, Evangelista M, Barsacchi G, Cremisi F: **MicroRNAs couple cell fate and developmental timing in retina.** *Proc Natl Acad Sci U S A* 2009, **106**(50):21179–21184.
50. Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM: **MacPherson D: miR-17-92 cooperates with RB pathway mutations to promote retinoblastoma.** *Genes Dev* 2011, **25**(16):1734–1745.
51. Aguirre G, Alligood J, O'Brien P, Buyukmihci N: **Pathogenesis of progressive rod-cone degeneration in miniature poodles.** *Invest Ophthalmol Vis Sci* 1982, **23**(5):610–630.
52. Aguirre G, O'Brien P: **Morphological and biochemical studies of canine progressive rod-cone degeneration. 3H-fucose autoradiography.** *Invest Ophthalmol Vis Sci* 1986, **27**(5):635–655.
53. Hackler L Jr, Wan J, Swaroop A, Qian J, Zack DJ: **MicroRNA profile of the developing mouse retina.** *Invest Ophthalmol Vis Sci* 2010, **51**(4):1823–1831.
54. Lukiw WJ, Surjyadipta B, Dua P, Alexandrov PN: **Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer's disease (AD) and in age-related macular degeneration (AMD).** *Int J Biochem Mol Biol* 2012, **3**(1):105–116.
55. Korenbrot JJ, Fernald RD: **Circadian rhythm and light regulate opsin mRNA in rod photoreceptors.** *Nature* 1989, **337**(6206):454–457.
56. Zhang Q, Acland GM, Wu WX, Johnson JL, Pearce-Kelling S, Tulloch B, Vervoort R, Wright AF, Aguirre GD: **Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration.** *Hum Mol Genet* 2002, **11**(9):993–1003.
57. Rachel RA, Li T, Swaroop A: **Photoreceptor sensory cilia and ciliopathies: focus on CEP290, RPGR and their interacting proteins.** *Cilia* 2012, **1**(1):22.
58. Suber ML, Pittler SJ, Qin N, Wright GC, Holcombe V, Lee RH, Craft CM, Lolley RN, Baehr W, Hurwitz RL: **Irish setter dogs affected with rod/cone dysplasia contain a nonsense mutation in the rod cGMP phosphodiesterase beta-subunit gene.** *Proc Natl Acad Sci U S A* 1993, **90**(9):3968–3972.
59. Ray K, Baldwin VJ, Acland GM, Blanton SH, Aguirre GD: **Cosegregation of codon 807 mutation of the canine rod cGMP phosphodiesterase beta gene and *rcd1*.** *Invest Ophthalmol Vis Sci* 1994, **35**(13):4291–4299.
60. Goldstein O, Kukekova AV, Aguirre GD, Acland GM: **Exonic SINE insertion in STK38L causes canine early retinal degeneration (erd).** *Genomics* 2010, **96**(6):362–368.
61. Chiba S, Amagai Y, Homma Y, Fukuda M, Mizuno K: **NDR2-mediated Rabin8 phosphorylation is crucial for ciliogenesis by switching binding specificity from phosphatidylserine to Sec15.** *EMBO J* 2013, **32**(6):874–885.
62. Ingenuity systems. [<http://www.ingenuity.com>]
63. microRNA.org website. [<http://www.microRNA.org>]
64. Betel D, Koppal A, Agius P, Sander C, Leslie C: **Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites.** *Genome Biol* 2010, **11**(8):R90.
65. Livak KJ, Schmittgen TD: **Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-delta delta C(T)} method.** *Methods* 2001, **25**(4):402–408.
66. Edgar R, Domrachev M, Lash AE: **Gene expression omnibus: NCBI gene expression and hybridization array data repository.** *Nucleic Acids Res* 2002, **30**(1):207–210.
67. Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, Qin Y, Sun Z, Zheng X: **miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells.** *BMC Cancer* 2010, **10**:354.
68. Yuva-Aydemir Y, Simkin A, Gascon E, Gao FB: **MicroRNA-9: functional evolution of a conserved small regulatory RNA.** *RNA Biol* 2011, **8**(4):557–564.
69. Bejarano F, Smibert P, Lai EC: **miR-9a prevents apoptosis during wing development by repressing drosophila LIM-only.** *Dev Biol* 2010, **338**(1):63–73.
70. Olive V, Bennett MJ, Walker JC, Ma C, Jiang J, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L: **miR-19 is a key oncogenic component of mir-17-92.** *Genes Dev* 2009, **23**(24):2839–2849.
71. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanasi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM: **MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.** *Proc Natl Acad Sci U S A* 2008, **105**(35):12885–12890.
72. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C: **MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation.** *Circ Res* 2007, **100**(11):1579–1588.
73. Park JK, Lee EJ, Esau C, Schmittgen TD: **Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.** *Pancreas* 2009, **38**(7):e190–9.
74. Liu J, van Mil A, Vrijksen K, Zhao J, Gao L, Metz CH, Goumans MJ, Doevendans PA, Slijter JP: **MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1.** *J Cell Mol Med* 2011, **15**(7):1474–1482.
75. Wang HQ, Yu XD, Liu ZH, Cheng X, Samartzis D, Jia LT, Wu SX, Huang J, Chen J, Luo ZJ: **Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degeneration by targeting FADD and caspase-3.** *J Pathol* 2011, **225**(2):232–242.
76. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, Jia ZF, Yang WD, Wang GX, Jiang T, You YP, Pu PY, Cheng JQ, Kang CS: **MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma.** *Mol Cancer* 2010, **9**:229.

77. Ma L, Liu J, Shen J, Liu L, Wu J, Li W, Luo J, Chen Q, Qian C: **Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells.** *Cancer Biol Ther* 2010, **9**(7):554–561.
78. Lin CJ, Gong HY, Tseng HC, Wang WL, Wu L: **miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines.** *Biochem Biophys Res Commun* 2008, **375**(3):315–320.
79. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahdaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhøi BP, Kjems J, Borre M, Orntoft TF: **Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro.** *Cancer Res* 2009, **69**(11):4851–4860.
80. Wu J, Qian J, Li C, Kwok L, Cheng F, Liu P, Perdomo C, Kotton D, Vaziri C, Anderlind C, Spira A, Cardoso WW, Lu J: **miR-129 regulates cell proliferation by downregulating Cdk6 expression.** *Cell Cycle* 2010, **9**(9):1809–1818.
81. Silva VA, Poleskaya A, Sousa TA, Correa VM, Andre ND, Reis RI, Kettelhut IC, Harel-Bellan A, De Lucca FL: **Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocin-induced diabetic rats.** *Mol Vis* 2011, **17**:2228–2240.
82. Kole AJ, Swahari V, Hammond SM, Deshmukh M: **miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis.** *Genes Dev* 2011, **25**(2):125–130.
83. Park SY, Lee JH, Ha M, Nam JW, Kim VN: **miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42.** *Nat Struct Mol Biol* 2009, **16**(1):23–29.
84. Liu X, Nelson A, Wang X, Kanaji N, Kim M, Sato T, Nakanishi M, Li Y, Sun J, Michalski J, Patil A, Basma H, Rennard SI: **MicroRNA-146a modulates human bronchial epithelial cell survival in response to the cytokine-induced apoptosis.** *Biochem Biophys Res Commun* 2009, **380**(1):177–182.
85. Suzuki Y, Kim HW, Ashraf M, Haider HK: **Diazoxide potentiates mesenchymal stem cell survival via NF-kappaB-dependent miR-146a expression by targeting Fas.** *Am J Physiol Heart Circ Physiol* 2010, **299**(4):H1077–82.
86. Hou Z, Xie L, Yu L, Qian X, Liu B: **MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis.** *Med Oncol* 2012, **29**(2):886–892.
87. Paik JH, Jang JY, Jeon YK, Kim WY, Kim TM, Heo DS, Kim CW: **MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma.** *Clin Cancer Res* 2011, **17**(14):4761–4771.

doi:10.1186/1471-2164-15-172

Cite this article as: Genini et al.: Altered miRNA expression in canine retinas during normal development and in models of retinal degeneration. *BMC Genomics* 2014 **15**:172.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

